New radioactive drug shows promise for tough prostate cancer

NCT ID NCT04506567

Ongoing Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a radioactive drug called 225Ac-J591 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part finds a safe dose and schedule, and the second part checks if the drug lowers PSA levels by more than half. About 60 men will take part, receiving the drug in one or more cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 225Ac-J591 (a radioactive drug targeting prostate cancer cells)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early-phase trial with only 60 participants, so the drug may not work as hoped or may cause severe side effects. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Brooklyn Methodist Hospital - New York Presbyterian

Brooklyn, New York, 11215, United States
Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.